At AgenTus, we are taking a multi-platform approach to leverage complementary cell therapy approaches, including T Cell Receptor (TCR) and Chimeric Antigen Receptor (CAR) technologies.


We will apply proprietary TCR platforms to identify, characterize, optimize, and – when necessary – create de novo T Cell Receptors (TCRs) directed against tumor-specific antigens to engineer immune effector cells. Our TCR platform is designed to enable AgenTus to efficiently optimize T-Rx™, a mammalian TCR display platform and fully human receptors to advance novel TCRs as components of living drugs. We also plan to employ natural and engineered CARs as an important cell therapy approach to supercharge human immune effector cells to seek and destroy cancer.

The AgenTus platform will be primarily designed around the following emerging capabilities within our portfolio of technologies:

  • T-Rx™ Platform: T-Rx is a precision discovery platform designed to enable the discovery of novel TCRs and CARs to create living drugs to treat a broad range of patients and types of cancers.  T-Rx was invented and developed as an integrated platform to identify, characterize and create new antigen-targeting TCRs with optimal functional properties.  T-Rx can also be used to guide the design of CARs.  By balancing activity and selectivity, we intend to engineer and select TCRs and CARs that enable living drugs to effectively seek out, recognize, and destroy cancer cells while sparing non-cancerous tissues.
  • PTT Neo-antigens: Our discovery efforts for living drugs will leverage novel tumor-specific neo-antigens, including promising phosphopeptide tumor targets (PTTs).  PTTs are a large class of cancer-specific neo-antigens that are shared amongst many cancers, unlike most mutation-based neo-antigens. These neo-antigens are recognized by TCRs which can be engineered into living drugs.
  • Autologous and Allogeneic Manufacturing: We intend to employ both autologous and allogeneic manufacturing processes at different stages of development. We will aim to develop living drugs in practical, off-the-shelf formats that would be scalable, straightforward to administer, and efficacious for both solid and liquid tumors.


What are Adoptive Cell Therapies, including CAR-T and TCR?

Immunotherapy has become a cornerstone of today’s cancer treatments.  Recently, Adoptive Cell Therapies, or ACTs have been in the spotlight with the first approved therapy being a CAR-T, or Chimeric Antigen Receptor T cell therapy.  CARs are designed to reprogram cells by combining the specificity of an antibody with the cytotoxic and memory function of T cells.

TCRs, or T Cell Receptor therapies, represent the next generation opportunity to empower immune effector cells for ACT. TCRs recognize tumor-specific proteins inside of cells and, therefore, require precise characterization and, in many cases, engineering of tumor-antigen-specific TCRs.  ACT utilizing TCRs will open new possibilities beyond CAR-based approaches, and in addition, TCR and ACT CAR approaches offer complementary ways to treat cancer.

Back to Top